Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1800722 | 0.80 | CA1 (0.46) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL1578413 | 0.76 | CA1 (0.45) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL1578411 | 0.76 | CA1 (0.45) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL4832922 | 0.75 | FOLH1 (0.49) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL4838067 | 0.75 | FOLH1 (0.49) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL3326851 | 0.75 | TSHR (0.44) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL3326846 | 0.75 | TSHR (0.44) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL27604048 | 0.75 | TSHR (0.44) | KMT2AHTTCYP2C19SMN1; SMN2TSHR | |
| SCHEMBL4382418 | 0.75 | CA1 (0.66) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL93708 | 0.75 | CA1 (0.66) | CA1CA2CA7CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951977-B2 | Process for producing hexahydrofurofuranol derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090176999-A1 | Process for producing hexahydrofurofuranol derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176999-A1 | Process for producing hexahydrofurofuranol derivative | DHFR, DHPS, CYP4B1 | CA1 4496/4885CA2 4696/4885CA7 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.